TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17492348
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of amino acids parenterally (Group 1)
Study: 17492348
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g of amino acids parenterally (Group 2)
Study: 15618054
Drug: Deferoxamine (DEF)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine (DEF) 4 g i.v. infusion for 8 hours starting immediately after the induction of anaesthesia (group D)
Study: 15618054
Drug: Dextrose solution
Normalized name: Dextrose solution
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose solution as placebo for 8 hours (group C)
Study: 15618054
Drug: Deferoxamine (DEF)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine (DEF) infusion in patients with lower EF (below 38%)
Study: 15618054
Drug: Deferoxamine (DEF)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine (DEF) infusion in patients with higher EF (above 38%)
Study: 10457621
Drug: Transfer-preparation letter
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer-preparation letter and verbal explanation
Study: 10457621
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no transfer-preparation letter)
Study: 8543357
Drug: Vancomycin at
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin at a concentration of 10 mg/l
Study: 2111629
Drug: Flow setting
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flow setting A (VFG of 75 ml.min‐1.kg‐1 and VE of 150 ml.min‐1.kg‐1)
Study: 2111629
Drug: Flow setting
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flow setting B (VFG of 110 ml.min‐1.kg‐1 and VE of 175 ml.min‐1.kg‐1)
Study: 85583
Drug: Zinc administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc administration (0.02 mg Zn per kg of body weight in the form of zinc sulphate)
Study: 31043691
Drug: Daily TMP/SXT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily TMP/SXT
Study: 24015717
Drug: Glucose solutions
Normalized name: glucose Injectable Solution
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solutions containing soy‐soluble polysaccharides (6%)
Study: 24015717
Drug: Glucose solutions
Normalized name: glucose Injectable Solution
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solutions containing flaxseed gum (0.7%)
Study: 24015717
Drug: Glucose solutions
Normalized name: glucose Injectable Solution
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solutions containing guar gum (0.23%)
Study: 24015717
Drug: Fiber‐fortified fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber‐fortified fluid and gelled dairy‐based study treatments
Study: 11222787
Drug: Remacemide 150
Normalized name: Remacemide
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide 150 mg/d
Study: 11222787
Drug: Remacemide 300
Normalized name: Remacemide
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide 300 mg/d
Study: 3412591
Drug: Amitriptyline (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (12.5 to 150 mg/d)
Study: 3412591
Drug: Lorazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.5 to 6 mg/d)
Study: 28922591
Drug: Olanzapine (2.5-20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5-20.0 mg/d)
Study: 25593016
Drug: Docetaxel (75mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75mg/m² IV every 21 days) with PX-866 (8mg PO daily)
Study: 23412986
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 3 mg/kg/d for 3 months
Study: 23412986
Drug: Propranolol 1
Normalized name: propranolol 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 1 mg/kg for 3 months
Study: 22321321
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone hydrochloride once daily for 16 weeks
Study: 14745704
Drug: PIV3-cp45 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIV3-cp45 vaccine
Study: 31527299
Drug: Non-randomized surgical
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-randomized surgical treatment
Study: 23692328
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of 150-200 ml milk
Study: 23692328
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly intake of 150-200 ml milk
Study: 23692328
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (daily and twice weekly)
Study: 21502577
Drug: Atopaxar (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopaxar (400 mg loading dose followed by 50, 100, or 200 mg daily)
Study: 8715845
Drug: Rectal temperatures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal temperatures
Study: 1398956
Drug: Single 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 x 10(8)‐CFU dose of live oral recombinant cholera vaccine CVD 103‐HgR
Study: 3987797
Drug: Trimebutine 100
Normalized name: trimebutine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine 100 mg i.v.
Study: 3358881
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg three times daily
Study: 28417910
Drug: L-CHO
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-CHO
Study: 14749569
Drug: Topical autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical autologous platelet‐enriched plasma combined with bovine collagen and thrombin (PCT)
Study: 14749569
Drug: Gelfoam/thrombin (G/T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelfoam/thrombin (G/T)
Study: 11148527
Drug: pH‐dependent, enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH‐dependent, enteric‐coated peppermint oil capsules
Study: 9631143
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human insulin-like growth factor type 1 (rhIGF-1)
Study: 9631143
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of rhGH and rhIGF-1
Study: 9631143
Drug: All therapies
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All therapies (rhGH, rhIGF-1, combination)
Study: 7829435
Drug: Dose schedule
Normalized name: hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose schedule No.1 (group 2)
Study: 7829435
Drug: Dose schedule
Normalized name: hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose schedule No.2 (group 3)
Study: 30816056
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg/day
Study: 20947174
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (3-12 mg/day) as adjunctive therapy
Study: 20947174
Drug: Mood stabilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood stabilizer monotherapy (valproate or lithium)
Study: 19277690
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg methyl‐ergometrine intramuscularly
Study: 15472840
Drug: Live, attenuated,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated, cold-adapted influenza vaccine (CAIV-T)
Study: 11682400
Drug: tandospirone 10
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tandospirone 10 mg (T10 group)
Study: 11682400
Drug: tandospirone 30
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tandospirone 30 mg (T30 group)
Study: 11682400
Drug: diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 10 mg (D group)
Study: 3680600
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg nortriptyline test dose
Study: 3680600
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg nortriptyline
Study: 3680600
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg nortriptyline
Study: 28085707
Drug: Citicoline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (100 mg twice a day)
Study: 21371281
Drug: Preventive ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive ceftriaxone treatment (2 g, given every 24 h intravenously for four days)
Study: 21371281
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care without preventive antibiotic treatment
Study: 21371281
Drug: Preventive ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive ceftriaxone treatment
Study: 17202203
Drug: Sealed capsule
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealed capsule irrigation (SCI) using distilled water for 2 minutes after phacoemulsification
Study: 15189176
Drug: Subcutaneous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epoetin alfa administration (group A)
Study: 15189176
Drug: Intravenous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epoetin alfa administration (group B)
Study: 15189176
Drug: Intravenous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epoetin alfa administration (group A after switch)
Study: 15189176
Drug: Subcutaneous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epoetin alfa administration (group B after switch)
Study: 8988824
Drug: Mivacurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.15 mg.kg-1 followed by 0.1 mg.kg-1
Study: 8988824
Drug: Rocuronium 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.9 mg.kg-1 followed by placebo
Study: 8988824
Drug: Divided dose
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided dose mivacurium
Study: 3508426
Drug: DMSO (hydroxyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSO (hydroxyl radical scavenger), administered locally 5 times a day for one week
Study: 3508426
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered for one week
Study: 24887747
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol propionate 0.05% applied three times a day
Study: 22383268
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive group therapy
Study: 10599260
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg once or twice a day)
Study: 10599260
Drug: Amoxicillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (3 g/d), Amoxicillin/clavulanic acid (1500 mg/d), Ceftriaxone (1-4 g/d)
Study: 7499116
Drug: Investigational direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational direct compression tablet
Study: 1449568
Drug: Corticosteroids in
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids in combination with albuterol
Study: 1449568
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with different corticosteroids in combination with albuterol
Study: 30289802
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nutrition supplementation and education
Study: 20660677
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg intravenous infusion of PRO 140
Study: 20660677
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg intravenous infusion of PRO 140
Study: 17986493
Drug: Cardiac-resynchronization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac-resynchronization therapy (CRT)
Study: 16321612
Drug: Nicotine vaccine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine vaccine (200 microg)
Study: 16321612
Drug: Nicotine vaccine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine vaccine (50 microg)
Study: 16321612
Drug: Nicotine vaccine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine vaccine (100 microg)
Study: 16321612
Drug: Nicotine vaccine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine vaccine (50, 100, 200 microg)
Study: 8065789
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion system with 0.125% plain bupivacaine
Study: 2903604
Drug: Lidocaine 1
Normalized name: lidocaine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1 mg kg‐1
Study: 31645442
Drug: NZ8123-HPV16-optiE7 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZ8123-HPV16-optiE7 vaccine (5 × 109 CFU/mL)
Study: 31645442
Drug: NZ8123-HPV16-optiE7 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZ8123-HPV16-optiE7 vaccine (1 × 1010 CFU/mL)
Study: 31645442
Drug: NZ8123-HPV16-optiE7 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZ8123-HPV16-optiE7 vaccine (1 × 109 CFU/mL)
Study: 11072157
Drug: Preoperative chemo-radiation
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative chemo-radiation (4760 cGy to primary and lymph nodes with concurrent chemotherapy: cisplatin/5-FU)
Study: 1547683
Drug: Pork insulin
Normalized name: Pork insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pork insulin
Study: 3884408
Drug: Lormetazepam (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (oral drops)
Study: 23912798
Drug: MTX +
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX + intravenous steroid
Study: 22982023
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) treatment for 30 months
Study: 22982023
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after stopping ICS treatment for 24 months
Study: 20381890
Drug: Self-administered intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intervention to assist patients in formulating plans for self-monitoring of blood glucose (SMBG)
Study: 11889577
Drug: Antioxidant cocktail
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant cocktail (vitamin E 500 mg/day, beta-carotene 30 mg/day, vitamin C 1 g/day for last 15 days)
Study: 8824473
Drug: Microemulsion formulation
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion formulation of cyclosporine
Study: 10071350
Drug: Original formulation
Normalized name: Zegerid (Original Formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original formulation of cyclosporine
Study: 7675951
Drug: Caffeine 75
Normalized name: caffeine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 75 mg
Study: 2286708
Drug: Fluphenazine (10-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine (10-30 mg/day)
Study: 7434788
Drug: Sulindac 200-400
Normalized name: sulindac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 200-400 mg/day for 4 weeks
Study: 7434788
Drug: Sulindac 200
Normalized name: sulindac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 200 mg in 10 healthy volunteers
Study: 27718637
Drug: New L-T4
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: New L-T4 formulation (600 μg)
Study: 27718637
Drug: Current L-T4
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Current L-T4 formulation (600 μg)
Study: 27718637
Drug: L-T4 tablets
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-T4 tablets (50 μg, 100 μg, 200 μg)
Study: 21860291
Drug: Prescription for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription for refills
Study: 15549369
Drug: Hot treatment
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot treatment (immersion in hot water at 43 degrees C for 16.0 min)
Study: 15549369
Drug: Hot treatment
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot treatment
Study: 11572325
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) and oxandrolone therapy
Study: 9260058
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with autotransplantation
Study: 9260058
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy (bisphosphonates and erythropoietin)
Study: 3663884
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of quinidine gluconate and procainamide hydrochloride
Study: 3663884
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose administration of quinidine gluconate and procainamide hydrochloride
Study: 28540562
Drug: Home-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based oral fluid rapid HIV self-testing
Study: 25070393
Drug: Control (blister
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (blister pack solution)
Study: 23127342
Drug: Inhaled Salmeterol/fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Salmeterol/fluticasone (SF) delivered by a metered-dose inhaler with a spacer
Study: 23127342
Drug: Inhaled nebulized
Normalized name: Hydra-Neb Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nebulized ipratropium/terbutaline/budesonide (ITB)
Study: 23127342
Drug: Inhaled Salmeterol/fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Salmeterol/fluticasone (SF)
Study: 18515448
Drug: 3-day taper
Normalized name: Zema-Pak 13-Day TaperPak
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day taper
Study: 18515448
Drug: 14-day taper
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day taper
Study: 18515448
Drug: short half-life
Approvals — FDA: no, EMA: no, PMDA: no
Description: short half-life antidepressants
Study: 15733932
Drug: L-5-hydroxytryptophan (5-HTP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan (5-HTP; 4 mg/kg in non enteric-coated tablets)
Study: 10349695
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon alfa-2b (rIFN-alpha 2b) plus oral ribavirin (1,000 or 1,200 mg)
Study: 10349695
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon alfa-2b (rIFN-alpha 2b) monotherapy
Study: 10349695
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (rIFN-alpha 2b alone and combination therapy)
Study: 1772105
Drug: RU41740 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU41740 (2 mg daily for one week in the first month, 1 mg daily for one week in the second month)
Study: 7075104
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg Digoxin + Placebo (PL2)
Study: 7075104
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg Digoxin + Quinidine (Q)
Study: 7075104
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg Digoxin
Study: 7075104
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg Digoxin + Sparteine (SP)
Study: 24863486
Drug: PsA-TT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PsA-TT vaccine (Meningococcal group A polysaccharide conjugated to tetanus toxoid)
Study: 24863486
Drug: Mencevax ACWY
Normalized name: meningococcal ACWY, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mencevax ACWY (quadrivalent plain polysaccharide vaccine)
Study: 22277697
Drug: 18% benzocaine/2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18% benzocaine/2% tetracaine gel
Study: 17329509
Drug: 0.87 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.87 g/d E2 gel
Study: 17329509
Drug: 1.7 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 g/d E2 gel
Study: 17329509
Drug: 2.6 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6 g/d E2 gel
Study: 15215483
Drug: Folate therapy
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate therapy (1 mg of folic acid, 5 mg of vitamin B6, and 1 mg of vitamin B12 intravenously, followed by daily oral doses of 1.2 mg of folic acid, 48 mg of vitamin B6, and 60 microg of vitamin B12 for six months)
Study: 9509065
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg orally for 4 days at 1700 hours